Vous n'êtes pas encore inscrit ?Inscription
“Acticor Biotech is a clinical stage biotech company, developing an innovative drug for the treatment of acute thrombotic diseases, including the acute phase of ischemic stroke.
Acticor Biotech is a spin-off company from Inserm (French National Institute of Health and Medical Research) founded in November 2013. The Headquarter is located in the Inserm U1148 building inside the Bichat Hospital in Paris.
Acticor Biotech is developing glenzocimab (ACT017), a humanized Antibody Fragment (Fab). The therapeutic candidate is directed against a novel target of major interest, the platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of glenzocimab and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition.” From acticor-biotech.com